




















Material Issues	Related SDGs	Main Initiatives and Results		FY2023	FY2022	FY2021	Scope of data collection
①Innovative pharmaceuticals and healthcare services	 	Creating new drugs, adding indications, changing dosage and administration, adding formulations, and providing around the pill solutions	Number of approvals (Medium-Term Management Plan 21-25, cumulative)	29	24 * 4	13	(Global)
			Number of solutions provided to patients (Medium-Term Management Plan 21-25, cumulative)	5	3	0	(Global)
			Number of development pipelines	17	20	27	(Global)
			Awards received for drug discovery (total since 2007 merger)	22	21	21	(Global)
			Number of partnering projects (Medium-Term Management Plan 21-25, cumulative)	15	11	6	(Global)
			Medium-Term Management Plan 21-25 new product sales volume by year	・ 654 packs (Therapeutic drugs for neuromyelitis optica spectrum disorders) ・ 27,651 packs (Therapeutic drugs for tardive dyskinesia) ・ 91,023 packs (Therapeutic drugs for amyotrophic lateral sclerosis, oral suspension) ・ 50,345 packs (5 combined vaccine)	・ 299 packs (Therapeutic drugs for neuromyelitis optica spectrum disorders) ・ 6,507 packs (Therapeutic drugs for tardive dyskinesia) ・ 24,587 packs (Therapeutic drugs for amyotrophic lateral sclerosis, oral suspension)	123 packs (Therapeutic drugs for neuromyelitis optica spectrum disorders)	(Global)
②Quality assurance and stable supply	 	Building systems for the stable supply of reliable pharmaceuticals, and appropriate responses to questions about quality	Number of product recalls (class I, II, and III)	class I 0 class II 2 class III 0	class I 0 class II 1 class III 0	class I 0 class II 1 class III 0	(Japan)
			Customer satisfaction with questions about quality	91.2%	92.9%	92.4%	(Japan)
③Appropriate use of products	 	Establishing a drug consultation center, collecting safety information, and providing information related to the appropriate use of products	Number of external presentations on clinical research (papers/academic conferences, etc.)	105	84	77	(Global)
			Instances of safety information collected	Domestic : 22,893 Overseas : 42,393	Domestic : 20,200 Overseas : 49,600	Domestic : 14,600 Overseas : 54,100	(Global)
④Access to healthcare	  	Supporting patients, developing therapeutic drugs for intractable and rare diseases, promoting project for infectious diseases that are prevalent in developing countries	Number of subsidized patient organizations (cumulative, total)	282	219	167	(Global)
			Number of health support website visitors	20.46 million	24.25 million	31.44 million	(Global)
			Number of pipelines for intractable and rare diseases	8	8 * 4	9	(Global)
			Number of approvals for intractable and rare diseases (Medium-Term Management Plan 21-25)	4	4 * 4	1	(Global)
			Number and stage of infectious disease treatment projects for developing countries	3 (Non-clinical)	3 (Non-clinical)	2 (Non-clinical)	(Global)
			Number of health support programs in developing countries	Vaccine: 11,335 doses	Vaccine: 9,281 doses	Vaccine: 34,633 doses	(Global)
⑤Stakeholder engagement		Disseminating information and dialoging with stakeholders including customers, the general public, and employees	Employee awareness survey results (Sympathy/understanding of management philosophy, rewarding/motivation)	77% (total favorable)*1	77% (total favorable)*1	79% (total favorable)*1	(Global)
			Customer satisfaction survey results (7-point scale)	Overall satisfaction : 5.00 Sympathy : 5.09 Necessity : 5.51	Overall satisfaction : 5.11 Sympathy : 5.12 Necessity : 5.62	Overall satisfaction : 5.05 Sympathy : 5.09 Necessity : 5.56	(Japan)
⑥ Employee health, diversity and inclusion	  	Promoting health management and improving work environment where all employees can play an active role	Employee survey results (Wellness item)	85% (total favorable)*1	84% (total favorable)*1	85% (total favorable)*1	(Global)
			Employee survey results (Diversity and respect for individuals)	81% (total favorable)*1	79% (total favorable)*1	81% (total favorable)*1	(Global)
			Diversity of management	25.0%*5	10.0%	20.8%	(Global)
⑦Environment-friendly business	   	Reducing environmental impact in corporate activities and educating employees to raise environmental awareness	GHG emissions (vs. fiscal 2019)	29.9% reduction	25.8% reduction*2	19.9% reduction*2	(Global)
			Amount of water withdrawal (vs. fiscal 2019)	38.1% reduction	37.5% reduction*2	31.4% reduction*2	(Global)
			Amount of final waste disposed (vs. fiscal 2019)	70.9% reduction	52.8% reduction*2	1.1% reduction*2	(Japan)
⑧Ethics, fairness and integrity	 	Working to cultivate an awareness of compliance issues, establishing and observing a variety of policies, and establishing hotlines	Surveying employee awareness on compliance (Employee awareness survey / 5 points is a perfect score)	96% (total favorable)*1	95% (total favorable)*1*3	4.51 points	(Global)
			Customer satisfaction survey results (corporate image) (7-point scale)	Compliance: 5.09 Confidence : 5.23	Compliance: 5.15 Confidence : 5.31	Compliance: 5.14 Confidence : 5.29	(Japan)

*1 : Total favorable is the total score of the top two response choices (Agree/Tend to Agree).

*2: Due to the companies included in the calculation withdrawing from business and reorganizing their facilities, results from FY2019 onwards have also changed.

*3: In accordance with changes to survey methods, FY2022 results and the scope of the survey have also changed.

*4: FY2022 results were revised to account for some omissions and for revisions to aggregation methods.

*5: Due to a reorganization of overseas consolidated companies, the companies targeted for aggregation were revised.